

# A Prospective Randomised Comparison of CMF versus Sequential Epirubicin Followed by CMF as Adjuvant Chemotherapy for Women with Early Breast Cancer

<b>Submission date</b> 19/08/2002	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 19/08/2002	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 08/10/2012	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

<http://cancerhelp.cancerresearchuk.org/trials/national-breast-cancer-study-of-epirubicin-as-adjuvant-therapy>

## Contact information

### Type(s)

Scientific

### Contact name

Dr - -

### Contact details

UKCCCR Register Co-ordinator  
MRC Clinical Trials Unit  
222 Euston Road  
London  
United Kingdom  
NW1 2DA

## Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

## Secondary identifying numbers

BR9601

# Study information

## Scientific Title

## Study objectives

Not provided at time of registration

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Not provided at time of registration

## Study design

Randomised controlled trial

## Primary study design

Interventional

## Secondary study design

Randomised controlled trial

## Study setting(s)

Not specified

## Study type(s)

Not Specified

## Participant information sheet

## Health condition(s) or problem(s) studied

Breast cancer

## Interventions

1. Group A: Chemotherapy, cyclophosphamide, methotrexate and 5-fluorouracil (CMF) repeated every 3 weeks for eight cycles
2. Group B: Chemotherapy, epirubicin repeated every 3 weeks for four cycles followed by CMF repeated every 3 weeks for four cycles

## Intervention Type

Other

## Phase

Not Specified

## Primary outcome measure

Not provided at time of registration

**Secondary outcome measures**

Not provided at time of registration

**Overall study start date**

01/01/2000

**Completion date**

30/04/2001

## Eligibility

**Key inclusion criteria**

1. Histologically confirmed breast cancer
2. Histologically confirmed axillary node metastases
3. Fit to receive chemotherapy on either arm of the trial
4. Adequate hepatic, renal and bone marrow function
5. No previous chemotherapy
6. No prior or concomitant malignancy, except basal cell carcinoma or in situ carcinoma of the cervix
7. No bilateral breast tumours or locally advanced or metastatic breast cancer, including supraclavicular fossa metastases

**Participant type(s)**

Patient

**Age group**

Not Specified

**Sex**

Female

**Target number of participants**

Not provided at time of registration

**Key exclusion criteria**

Not provided at time of registration

**Date of first enrolment**

01/01/2000

**Date of final enrolment**

30/04/2001

## Locations

**Countries of recruitment**

England

United Kingdom

**Study participating centre**  
**UKCCCR Register Co-ordinator**  
London  
United Kingdom  
NW1 2DA

## **Sponsor information**

**Organisation**  
Pharmacia Ltd & Upjohn (UK)

**Sponsor details**  
Davy Avenue  
Milton Keynes  
United Kingdom  
MK5 8PH  
+44 (0)1908 661101  
info@adresco.co.uk

**Sponsor type**  
Industry

**Website**  
<http://www.pharmacia.com>

**ROR**  
<https://ror.org/04x4v8p40>

## **Funder(s)**

**Funder type**  
Industry

**Funder Name**  
Pharmacia and Upjohn (UK)

## **Results and Publications**

## Publication and dissemination plan

Not provided at time of registration

## Intention to publish date

## Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	02/11/2006		Yes	No